{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Squamous+Tumors&page=20", "query": { "condition": "Advanced Squamous Tumors", "page": 20 }, "page_size": 10 }, "pagination": { "page": 20, "page_size": 10, "total_count": 954, "total_pages": 96, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Squamous+Tumors&page=21&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Squamous+Tumors&page=19&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T21:08:19.492Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01063283", "title": "Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Advanced Non-squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab 7.5 mg/kg", "type": "DRUG" }, { "name": "Bevacizumab 15 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "18 Years to 89 Years" }, "enrollment_count": 20, "start_date": "2010-03", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2019-11-18", "last_synced_at": "2026-11-15T21:08:19.492Z", "location_count": 3, "location_summary": "Chicago, Illinois • Evanston, Illinois • Harvey, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" }, { "city": "Harvey", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01063283" }, { "nct_id": "NCT05127590", "title": "RBN-2397 in Combination With Pembrolizumab in Patients With SCCL", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Squamous Non-Small Cell Lung Carcinoma" ], "interventions": [ { "name": "RBN-2397", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ribon Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 50, "start_date": "2022-03-15", "completion_date": "2023-12", "has_results": false, "last_update_posted_date": "2023-07-03", "last_synced_at": "2026-11-15T21:08:19.492Z", "location_count": 4, "location_summary": "Newark, Delaware • Newnan, Georgia • Baton Rouge, Louisiana + 1 more", "locations": [ { "city": "Newark", "state": "Delaware" }, { "city": "Newnan", "state": "Georgia" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05127590" }, { "nct_id": "NCT03685591", "title": "PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasms", "Prostate Neoplasms", "Neoplasms, Squamous Cell", "Melanoma", "Mesothelioma", "Pancreatic Neoplasms", "Colorectal Neoplasms", "Carcinoma, Renal Cell", "Liver Neoplasms" ], "interventions": [ { "name": "PF-06952229", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-10-04", "completion_date": "2022-03-30", "has_results": true, "last_update_posted_date": "2024-06-26", "last_synced_at": "2026-11-15T21:08:19.492Z", "location_count": 15, "location_summary": "Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03685591" }, { "nct_id": "NCT02001623", "title": "Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Ovary Cancer", "Cervix Cancer", "Endometrium Cancer", "Bladder Cancer", "Prostate Cancer (CRPC)", "Esophagus Cancer", "Lung Cancer(NSCLC)", "Squamous Cell Carcinoma of the Head and Neck (SCCHN)" ], "interventions": [ { "name": "Tisotumab Vedotin (HuMax-TF-ADC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 195, "start_date": "2013-11-30", "completion_date": "2019-05-02", "has_results": true, "last_update_posted_date": "2021-12-29", "last_synced_at": "2026-11-15T21:08:19.492Z", "location_count": 8, "location_summary": "Orange, California • New Haven, Connecticut • Miami, Florida + 5 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT02001623" }, { "nct_id": "NCT03329950", "title": "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Non-small Cell Lung Cancer", "Breast Cancer", "Gastric Cancer", "Renal Cell Carcinoma", "Ovarian Cancer", "Cholangiocarcinoma", "Bladder Urothelial Carcinoma", "Pancreatic Adenocarcinoma", "Colorectal Cancer", "Esophageal Cancer", "Hepatic Cancer", "Head and Neck Cancer", "Primary Peritoneal Cancer", "Fallopian Tube Cancer", "Other Solid Tumors", "Diffuse Large B-cell Lymphoma (DLBCL)", "Mantle Cell Lymphoma", "Indolent B-cell Lymphomas", "Non-Hodgkin Lymphoma", "Follicular Lymphoma", "Lymphoplasmacytic Lymphoma", "Waldenstrom's Disease", "Marginal Zone Lymphoma", "Mucosa Associated Lymphoid Tissue", "Small Lymphocytic Leukemia" ], "interventions": [ { "name": "CDX-1140", "type": "DRUG" }, { "name": "CDX-301", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2017-12-01", "completion_date": "2022-09-13", "has_results": false, "last_update_posted_date": "2024-03-28", "last_synced_at": "2026-11-15T21:08:19.492Z", "location_count": 11, "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Augusta, Georgia + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03329950" }, { "nct_id": "NCT02192541", "title": "Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Ziv-Aflibercept", "type": "DRUG" }, { "name": "Ganetespib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 5, "start_date": "2014-12-02", "completion_date": "2016-02-25", "has_results": true, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-11-15T21:08:19.492Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02192541" }, { "nct_id": "NCT01305772", "title": "Identification of Gene Expression Signature for Panitumumab Sensitivity in Untreated Locally Advanced SCCHN", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck" ], "interventions": [ { "name": "Panitumumab", "type": "DRUG" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Neal Ready", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2011-01", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2014-08-29", "last_synced_at": "2026-11-15T21:08:19.492Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Durham, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01305772" }, { "nct_id": "NCT00004227", "title": "Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "1999-04", "completion_date": "2008-05", "has_results": false, "last_update_posted_date": "2014-02-06", "last_synced_at": "2026-11-15T21:08:19.492Z", "location_count": 3, "location_summary": "Lakewood, New Jersey • Long Branch, New Jersey • Somerville, New Jersey", "locations": [ { "city": "Lakewood", "state": "New Jersey" }, { "city": "Long Branch", "state": "New Jersey" }, { "city": "Somerville", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004227" }, { "nct_id": "NCT05538572", "title": "A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Glioblastoma", "Head and Neck Squamous Cell Carcinoma", "Malignant Mesothelioma", "Non-small Cell Lung Cancers", "Sarcoma", "Endometrial Cancer" ], "interventions": [ { "name": "PRT3645", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prelude Therapeutics Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2022-12-27", "completion_date": "2024-06-26", "has_results": false, "last_update_posted_date": "2024-07-01", "last_synced_at": "2026-11-15T21:08:19.492Z", "location_count": 12, "location_summary": "New Haven, Connecticut • Celebration, Florida • Miami, Florida + 8 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Celebration", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05538572" }, { "nct_id": "NCT03589339", "title": "NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Radiotherapy", "Immunotherapy", "Microsatellite Instability-High Solid Malignant Tumour", "Metastasis From Malignant Tumor of Liver", "Squamous Cell Carcinoma of Head and Neck", "Metastasis From Malignant Tumor of Cervix", "Metastatic Renal Cell Carcinoma", "Metastasis From Malignant Melanoma of Skin (Disorder)", "Metastatic Triple-Negative Breast Carcinoma", "Metastatic NSCLC", "Metastasis From Malignant Tumor of Bladder (Disorder)" ], "interventions": [ { "name": "NBTXR3", "type": "DRUG" }, { "name": "SABR", "type": "RADIATION" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Nanobiotix", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 145, "start_date": "2019-01-16", "completion_date": "2027-08-30", "has_results": false, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-11-15T21:08:19.492Z", "location_count": 13, "location_summary": "San Francisco, California • Tampa, Florida • Atlanta, Georgia + 9 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03589339" } ] }